Last reviewed · How we verify
JNJ-54861911-Therapeutic Dose
At a glance
| Generic name | JNJ-54861911-Therapeutic Dose |
|---|---|
| Also known as | RSC-385896, MTS-0385896A |
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants (PHASE1)
- A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants (PHASE1)
- A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JNJ-54861911-Therapeutic Dose CI brief — competitive landscape report
- JNJ-54861911-Therapeutic Dose updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI